Remdesivir, Favipiravir and Sinefungin, three nucleosidic products with potential antiviral properties against SARS-CoV-2

Abstract

In December 2019, an outbreak of pneumonia of unknown origin was reported in Wuhan, China. The causing agent was promptly recognised as a new coronavirus (CoV) titled as SARS-CoV-2. The accelerated set of scientific findings on SARS-CoV-2 provided in a record time a meaningful amount of potential drug targets. Current promising strategies to pharmacologically target SARS-CoV-2 are vaccines and repurposing drugs. Repurposing antivirals have the advantage of accelerated market approval because of the previously broad knowledge of the drug's behaviour in humans and the feasibility of combining the repurposed drugs with other ones to reach much more effective treatments. Nonetheless, more therapeutic trials are required to establish whether these drugs are indeed efficacious and safe against SARS-CoV-2. In this TFG report, through a previous analysis of the biology and activity of the virus, we will review three current potential antivirals against SARS-CoV-2: Remdesivir, Favipiravir and Sinefungin. Concretely, the chemical methodologies adopted for either development and synthesis, mode of biological action and therapeutic and pharmacological properties will be specifically treated for each antiviral